Cochrane · systematic review · CD006254
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients
Ballinger, AE, Palmer, SC, Nistor, I, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 20%Very low 0 · 0%Low 0 · 0%Moderate 1 · 20%High 3 · 60%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings for dialysis patients
Population: adults with CKD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (8 months) | RR 0.97 [0.89, 95] | 14 studies · 6893 participants | High |
Parathyroidectomy (9 months) | RR 0.49 [0.4, 0.59] | 5 studies · 4893 participants | High |
Hypocalcaemia (7 months) | RR 6.98 [5.1, 9.53] | 12 studies · 6415 participants | High |
Nausea (7 months) | RR 2.02 [1.45, 2.81] | 12 studies · 6450 participants | Moderate |
GFR category G3a‐G4 | no estimate extracted | 3 participants | Ungraded |